Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex vs Neostigmine for Postoperative Pulmonary Complications in Elderly
NCT02861131Phase 4Completed
- Sponsor
- Oregon Health & Science University
- Start
- Jan 2017
- Primary completion
- Apr 2018
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of Sugammadex in postoperative pulmonary complications (PPC) and neuromuscular blockade (NMB) (2 arms), sponsored by Oregon Health & Science University. Primary endpoint: Number of Participants With a Postoperative Pulmonary Complication at 1 week. Started Jan 2017; status: completed.
02
Drugs
Sugammadex
03
Conditions
postoperative pulmonary complications (PPC)neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT02861131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02861131.